Feasibility of Building a Biotech Industry
José A. Buxadó *
Department of Business Intelligence, Center for Genetic Engineering and Biotechnology, Ave. 31 e/158 y 190, Cubanacán, P.O. Box 6162, CP 10600, La Habana, Cuba.
Miladys Limonta Fernández
Center for Genetic Engineering and Biotechnology, Ave. 31 e/158 y 190, Cubanacán, P.O. Box 6162, CP 10600, La Habana, Cuba.
Gerardo E. Guillén Nieto
Center for Genetic Engineering and Biotechnology, Ave. 31 e/158 y 190, Cubanacán, P.O. Box 6162, CP 10600, La Habana, Cuba.
Marta Ayala Ávila
Center for Genetic Engineering and Biotechnology, Ave. 31 e/158 y 190, Cubanacán, P.O. Box 6162, CP 10600, La Habana, Cuba.
*Author to whom correspondence should be addressed.
Abstract
The performance of Cuban biotechnology from 2008 to 2021 has shown a growing pipeline of valuable biomedical solutions. As the transformation of this sector into an industrial group has changed its R&D productivity and bio manufacturing capacity, we summarize here the results of R&D projects with impact on public health, constraints found in Cuba, lessons, and opportunities to develop this science-based industry in developing countries.
Keywords: Bio manufacturing, COVID-19, vaccine, know-how, innovation, R&D